Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “hold” rating restated by TheStreet in a research note issued on Friday, AnalystRatings.Net reports.
The analysts wrote, “Regeneron Pharmaceuticals (REGN) has been reiterated by TheStreet Ratings as a hold with a ratings score of C+. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company’s earnings per share.”
A number of other firms have also recently commented on REGN. Analysts at Piper Jaffray initiated coverage on shares of Regeneron Pharmaceuticals in a research note to investors on Wednesday. They set an “overweight” rating and a $376.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Regeneron Pharmaceuticals in a research note to investors on Tuesday. They now have a $309.00 price target on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Regeneron Pharmaceuticals from $251.00 to $274.00 in a research note to investors on Wednesday, November 6th. They now have a “hold” rating on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company’s stock. Regeneron Pharmaceuticals has a consensus rating of “Buy” and an average target price of $280.69.
In other Regeneron Pharmaceuticals news, Director George Sing sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $295.00, for a total value of $2,950,000.00. Following the completion of the sale, the director now directly owns 112,772 shares of the company’s stock, valued at approximately $33,267,740. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 292.88 on Friday. Regeneron Pharmaceuticals has a 52-week low of $154.16 and a 52-week high of $319.83. The stock has a 50-day moving average of $290.6 and a 200-day moving average of $267.6. The company has a market cap of $28.768 billion and a price-to-earnings ratio of 41.70.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $2.40 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.92 by $1.48. The company had revenue of $597.00 million for the quarter, compared to the consensus estimate of $501.93 million. During the same quarter last year, the company posted $1.89 earnings per share. Regeneron Pharmaceuticals’s revenue was up 39.6% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals will post $3.83 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.